Italy has emerged as one of the top-performing countries in the European Union in reducing cancer mortality, according to recent data from Eurostat and national health agencies. Between 2011 and 2021, age-standardised cancer death rates in Italy declined by approximately 15%, outpacing the EU average and placing the nation among the leaders in oncological outcomes alongside countries like Spain, Sweden, and Cyprus. This progress reflects sustained investments in early detection, equitable access to treatment, and nationwide prevention initiatives.
The downward trend continued into 2024, with preliminary estimates from Italy’s National Institute of Health (ISS) indicating around 14,000 fewer cancer-related deaths compared to the previous year. This decline spans multiple cancer types, including lung, colorectal, breast, and prostate cancers, and is attributed to a combination of reduced smoking rates, expanded screening programmes, and advances in targeted therapies, and immunotherapy. Experts caution, but, that disparities persist across regions, with southern Italy still lagging behind the north in screening uptake and survival rates for certain malignancies.
Despite these gains, cancer remains a leading cause of death in Italy and across Europe, accounting for over one in four fatalities in the EU, according to the European Cancer Information System (ECIS). In 2021, nearly 1.3 million people died of cancer in the 27-member bloc, with lung cancer being the most common cause of cancer death among men and breast cancer among women. Italy’s relative success highlights the impact of long-term public health strategies, but also underscores the need for continued vigilance as demographic ageing and lifestyle factors present ongoing challenges.
National Screening Programmes Drive Early Detection
A cornerstone of Italy’s progress has been its organised, population-based cancer screening programmes, which are fully integrated into the National Health Service (Servizio Sanitario Nazionale) and offered free of charge to eligible residents. These include biennial mammography for women aged 50–69, faecal immunochemical testing (FIT) every two years for colorectal cancer in adults aged 50–74, and cervical cancer screening via HPV testing or Pap smears for women aged 25–64. Participation rates, while improving, vary significantly by region, with northern areas routinely exceeding 60% uptake and some southern regions falling below 40%.
According to data published by Italy’s Ministry of Health in 2023, organised screening contributed to a 30% reduction in colorectal cancer mortality over the past decade and helped detect nearly 60% of breast cancers at an early, treatable stage. The ISS estimates that if national screening participation reached 70% uniformly across all regions, an additional 3,000 lives could be saved annually. Efforts to close this gap include mobile screening units, targeted outreach in underserved communities, and integration with primary care networks to improve follow-up after abnormal results.
In 2024, the Italian government launched a five-year, €1.2 billion oncology plan aimed at further reducing cancer mortality by 10% by 2029. The strategy includes expanding lung cancer screening for high-risk smokers using low-dose CT scans, increasing access to genomic testing for personalised treatment, and strengthening palliative care services. Funding is sourced from both national health budgets and EU recovery funds allocated under the NextGenerationEU initiative, with oversight by the Interministerial Committee for Health Policies.
Regional Disparities and Equity Challenges
While national averages show improvement, significant regional disparities persist in cancer outcomes. A 2023 analysis by the Italian Association of Medical Oncology (AIOM) revealed that five-year survival rates for colorectal cancer were 8% higher in Lombardy and Veneto than in Calabria and Sicily. Similar gaps exist for breast and lung cancer, driven by differences in healthcare infrastructure, specialist availability, and preventive care access. These disparities are closely correlated with socioeconomic factors, including income levels, education, and urbanisation.
Efforts to address these inequities include the “Equity in Cancer Care” initiative launched by the Ministry of Health in 2022, which allocates additional resources to hospitals in southern and insular regions to upgrade diagnostic equipment, train staff, and reduce waiting times. Early results from pilot programmes in Campania and Puglia show a 15% increase in screening participation and a 10% reduction in time-to-treatment initiation. However, independent experts note that sustained funding and long-term commitment are needed to achieve lasting change.
The Italian National Outcomes Programme (Programma Nazionale Esiti, PNE), managed by AGENAS (the National Agency for Regional Health Services), publishes annual performance metrics for hospitals and local health authorities, including cancer-specific indicators such as surgical volume, mortality rates, and adherence to clinical guidelines. This transparency tool has been credited with driving quality improvements, though critics argue it does not fully account for case complexity or social determinants of health.
Lifestyle Factors and Prevention Beyond Screening
Beyond screening, Italy’s progress in reducing cancer mortality is linked to broader public health successes, particularly in tobacco control. Adult smoking prevalence has declined from over 24% in 2000 to approximately 19% in 2023, according to ISS data, due to smoke-free laws, taxation, and public awareness campaigns. Lung cancer mortality rates among men have fallen by nearly 25% since 2010, reflecting this trend, while increases among women — linked to later uptake of smoking — remain a concern.
Diet and physical activity also play a role. Italy’s traditional Mediterranean diet, rich in fruits, vegetables, olive oil, and legumes, has been associated with lower risks of colorectal and breast cancer in multiple studies. However, rising rates of childhood obesity and sedentary behaviour, particularly in urban areas, pose emerging risks. The ISS reports that nearly 25% of Italian adolescents are overweight or obese, a trend that could influence future cancer incidence if not addressed.
Alcohol consumption, while lower than in some Northern European countries, remains a modifiable risk factor. The ISS estimates that alcohol contributes to approximately 4% of cancer cases in Italy, particularly those of the oral cavity, pharynx, larynx, oesophagus, liver, and breast. Public health messages promoting moderation are integrated into general wellness campaigns, though dedicated alcohol reduction strategies remain limited compared to tobacco initiatives.
Innovation in Treatment and Research
Italy’s strong clinical research infrastructure has contributed to improved survival through access to innovative therapies. The country participates in numerous European Organisation for Research and Treatment of Cancer (EORTC) trials and hosts several comprehensive cancer centres designated by the Organisation of European Cancer Institutes (OECI), including the IEO in Milan, the National Cancer Institute of Naples (Fondazione Pascale), and the CRO in Aviano. These centres provide access to cutting-edge treatments such as CAR-T cell therapy, immune checkpoint inhibitors, and PARP inhibitors, often through compassionate use programmes or early access pathways.
In 2023, the Italian Medicines Agency (AIFA) approved over 15 new oncology indications, including biomarker-driven treatments for non-small cell lung cancer and combination regimens for metastatic colorectal cancer. The National Oncology Plan 2023–2027 includes provisions to accelerate regulatory review for breakthrough therapies and expand molecular profiling in public hospitals to guide treatment decisions. Collaborative networks like the Italian Group for Cancer Epidemiology and Registry (AIRTUM) ensure that real-world data inform both clinical practice and policy.
Despite these advances, access to novel therapies can still be delayed by regional budgeting processes and variations in hospital formularies. Patient advocacy groups, such as FAVO (the Italian Federation of Volunteer Associations in Oncology), continue to call for greater uniformity in access and faster integration of innovations into standard care. AIFA has responded by strengthening its Health Technology Assessment (HTA) processes and increasing transparency in pricing and reimbursement decisions.
What This Means for Patients and Public Health
For individuals, the declining cancer mortality rate translates into tangible benefits: earlier diagnosis, more treatment options, and improved quality of life during and after care. Screening programmes remain the most effective tool for detecting cancer before symptoms arise, and public health officials urge eligible Italians to participate in scheduled tests, which can be arranged through local health authorities (ASLs) or primary care physicians. Invitations are typically sent by mail, but individuals can also proactively contact their ASL to check eligibility and schedule appointments.
From a system perspective, Italy’s experience demonstrates that sustained investment in prevention, equitable access to screening, and innovation in treatment can yield measurable reductions in cancer burden — even in the face of an ageing population. However, the persistence of regional inequities serves as a reminder that national averages can mask local challenges. Continued monitoring, targeted investment, and cross-sector collaboration will be essential to ensure that progress benefits all residents, regardless of geography or socioeconomic status.
Looking ahead, the next major milestone is the mid-term review of the National Oncology Plan 2023–2027, scheduled for release by the Ministry of Health in late 2025. This assessment will evaluate progress toward mortality reduction targets, screening participation goals, and equity benchmarks, using data from AGENAS, ISS, and regional health authorities. Stakeholders including AIOM, FAVO, and patient representatives are expected to contribute to the review process.
If you or someone you know is eligible for cancer screening, contact your local health authority or visit the official portal of the Italian Ministry of Health (salute.gov.it) for information on programme eligibility, test types, and how to schedule an appointment. Staying informed and proactive remains one of the most powerful steps individuals can take in the fight against cancer.